-
NAV$108.05
as of October 02, 2026 -
YTD RETURNS6.23%
as of October 02, 2026 -
Total Net Assets$1.03B
as of October 02, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
About PPH
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Why PPH
- Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders: Index methodology favors the largest companies in the industry
- Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Performance
Fees
Holdings
Portfolio
Sector Weightings (%) as at 30 Sep 2026
-
Sector
% of Net Assets -
Health Care
99.62 -
Other/Cash
0.38
Country Weightings (%) as at 30 Sep 2026
-
Country
% of Net Assets -
United States
67.84 -
United Kingdom
11.75 -
Denmark
5.60 -
Israel
4.75 -
Switzerland
3.61 -
France
3.35 -
Japan
2.71 -
Other/Cash
0.38